The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enzalutamide plus exemestane: A pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer.
Lee Steven Schwartzberg
No relevant relationships to disclose
Denise A. Yardley
No relevant relationships to disclose
Anthony D. Elias
Research Funding - Medivation
Manish R. Patel
No relevant relationships to disclose
Ayca Gucalp
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Amy C. Peterson
Employment or Leadership Position - Medivation
Alison L. Hannah
Consultant or Advisory Role - Medivation
Martha Elizabeth Blaney
Employment or Leadership Position - Medivation
Jackie Gibbons
Employment or Leadership Position - Medivation
Stock Ownership - Medivation
Iulia Cristina Tudor
Employment or Leadership Position - Medivation
Stock Ownership - Medivation
Joyce L. Steinberg
Employment or Leadership Position - Astellas Pharma
Patricia LoRusso
Employment or Leadership Position - Karmanos Cancer Institute
Jeffrey R. Infante
No relevant relationships to disclose
Clifford A. Hudis
No relevant relationships to disclose
Tiffany A. Traina
Consultant or Advisory Role - Eisai; Genentech; Prostrakan
Honoraria - Celgene; Eisai; Genentech; Merck; Prostrakan
Research Funding - AstraZeneca; Eisai; Genentech; Janssen; Medivation; Novartis; ZIOPHARM Oncology